Skip to main navigation
Skip to search
Skip to main content
University of Luebeck Home
English
Deutsch
Home
Research Units
Experts
Publications
Projects
Prizes
Spin-Offs
Activities
Media
Search by expertise, name or affiliation
Dostarlimab for Primary Advanced or Recurrent Endometrial Cancer
RUBY Investigators
Clinic of Gynecology and Obstetrics
Charles University
Overview
Fingerprint
Fingerprint
Dive into the research topics of 'Dostarlimab for Primary Advanced or Recurrent Endometrial Cancer'. Together they form a unique fingerprint.
Sort by
Weight
Alphabetically
Medicine & Life Sciences
Alopecia
11%
Body Surface Area
12%
Carboplatin
24%
Combination Drug Therapy
10%
Confidence Intervals
58%
DNA Mismatch Repair
12%
Endometrial Neoplasms
100%
Fatigue
9%
Immunotherapy
9%
Microsatellite Instability
39%
Nausea
9%
Neoplasms
3%
Paclitaxel
21%
Placebos
59%
Population
12%
Programmed Cell Death 1 Receptor
15%
Progression-Free Survival
39%
Random Allocation
10%
Randomized Controlled Trials
7%
Research Personnel
7%
Response Evaluation Criteria in Solid Tumors
13%
Safety
6%
Survival
11%
Therapeutics
3%